prospects in immunological therapy of cancer
immunogenic properties of a complex antigenic material extracted from neoplastic (TLP)
Journal: Journal Cellular Physiology, 221: 26-30, 2009
immunogenic properties of a complex antigenic material extracted from neoplastic (TLP)
Journal: Journal Cellular Physiology, 221: 26-30, 2009
Search made
long fight against cancer is seeing beyond the traditional instruments chemotherapy, radiology and surgery, the use of 'iimunoterapia. In this sense, of particular interest are the new approaches of immune therapy, through the use of drugs that restaurino reductions immunity (caused by cancer and / or cytostatic treatment physical and pharmacological) and the use of interferon or killers cells activated in the presence of interleukin-2. Another field of cancer immunotherapy that is proving fruitful and that of cancer markers .. The work that the group of Prof. Giulio Tarro held with the center of prof. Peden of Mantua has had the goal of seeking a cancer antigen (TLP signed) sufficiently immunogenic to induce cancer in a specific stimulus encolitico effective, whilst exploring the possibility of creating a certain laxity in the patient with the antigenic stimulus. These investigations have led to important results such as the discovery of the TLP (a protein released from human tumors) (European Patent No. 88830058.9, / The Hague 1998) and 'European license application (M. RM 92A 000506/1992) for synthetic peptides of the antigen for lung cancer .
Summary of research
The current research has now demonstrated unequivocally the presence of a tumor-associated antigens (TAA) managers: the induction of specific antibodies, delayed hypersensitivity reactions; blastizzazione of the peripheral lymphocytes of patients negotiations with TAA autologous and homologous previously sensitized, the lack of blastizzazione lymphocytes of healthy individuals and cancer that were not pretreated with the same antigen. Based on the experiences and places may think that the TLP, as immunogenic and specific mitogen, and finally as part of the envelope antigen of the tumor cells, may be valid approaches for cancer immunotherapy.
substances originate from two different tumor tissues (lung cancer, colon cancer TLP1-and-TLP2-) distinction made to increase the chances of congruence in the subject with atypical protein with those in the preparation. Many years of work have been spent to identify the essential parameters TLP antigen and then to verify its effectiveness as an anticancer therapeutic substance via the stimulation of the immune system of an organism which is naturally gifted. The TLP consists lipoglicoproteine \u200b\u200bsolubles, measuring between -61 48.1 Angstrom, has an isoelectric point below 7.0 and has a molecular weight of 214,000 dalton polymer consisting of monomers of about 54,000 daltons that has been analyzed before the establishment amino acid sequence, and then obtained the TLP II or protein released by tumor-derived antigen is a tumor surgically removed biochemically extracted, isolated, purified. Recently, the epitopes or parts of the same prosthetic antigens were sequentially with respect to certain lung cancers. A similar study was done for colon cancer while other studies are working on genitourinary cancers. Subsequently, synthetic peptides were obtained using sequence data for proteins studied previously and were prepared antibodies policlonaili in regard to these antigens. In conclusion, structural analysis were obtained carcinona pulmonary antigen and an antibody was developed in regard to this' antigen with which one could envisage the development of a diagnostic method for an antigen associated with lung tumors using antisera existing with the goal of early diagnosis of lung cancer. In addition, the antigen is purified to synthetic that can be used with active specific immunotherapy protocols already set, as target substances obtained directly from immunogenic tumors or produced by genetic engineering. The identification of the amino acid sequence is a collaboration with prof. Giulio Tarro Sbarro Institute in Philadelphia (USA). The structural analysis of lung cancer antigen has been successfully conducted to obtain information on amino acid sequence. II rationale that led to the identification of the peptide fragment described as an epitope of the antigen for lung cancer, took the cue from a study conducted by prof. Tarro on the purification and characterization of lung cancer antigen (TLP), noting that it was possible to obtain monoclonal antibodies immunizing mice with intact proteins. We are built, then, synthetic peptides as antigens to prepare antibodies to specific sites based on information of the partial sequence obtained. Since the protein is expressed in lung cancer, the production of antibodies against this antigen leads to the use of a screening test in respect of crude extracts from lung, toward the antigen protein and examine the preparation of a "cDNA library" by tumor material.
